Use of proton pump inhibitors increased the risk of hip fracture

A population-based case-control study

Hui Fen Chiu, Ya Wen Huang, Chih-Ching Chang, Chun Yuh Yang

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Purpose: To investigate whether the use of proton pump inhibitor (PPIs) was associated with an increased risk of hip fracture. Methods: We conducted a population-based case-control study in Taiwan. Data were retrospectively collected from the Taiwan National health Insurance Research Database. Cases included all patients with a newly diagnosed of hip fracture in 2005 and 2006 (n = 1241). The controls were pair matched to cases by age, sex, and index date. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by using multiple logistic regression. Results: Having been prescribed more than 28 defined daily dose (DDDs) of PPIs was associated with an increased risk for hip fracture in multivariate analyses (adjustments for matching variables and medication use) (at 29-70 DDDs, OR = 1.67, 95% CI = 1.11-2.51 and at >70 DDDs, OR = 2.51, 95% CI = 1.77-3.55). There was a significant trend toward increasing hip fracture risk with increasing cumulative DDDs of PPIs (p for trend <0.0001). Conclusions: This study provides evidence that PPIs use is associated with an increased risk of hip fracture in a dose-response manner.

Original languageEnglish
Pages (from-to)1131-1136
Number of pages6
JournalPharmacoepidemiology and Drug Safety
Volume19
Issue number11
DOIs
Publication statusPublished - 2010 Nov 1

Fingerprint

Proton Pump Inhibitors
Hip Fractures
Case-Control Studies
Population
Odds Ratio
Confidence Intervals
Taiwan
National Health Programs
Multivariate Analysis
Logistic Models
Databases
Research

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Epidemiology

Cite this

@article{736018bca9b149b2b82aef785f8bd01c,
title = "Use of proton pump inhibitors increased the risk of hip fracture: A population-based case-control study",
abstract = "Purpose: To investigate whether the use of proton pump inhibitor (PPIs) was associated with an increased risk of hip fracture. Methods: We conducted a population-based case-control study in Taiwan. Data were retrospectively collected from the Taiwan National health Insurance Research Database. Cases included all patients with a newly diagnosed of hip fracture in 2005 and 2006 (n = 1241). The controls were pair matched to cases by age, sex, and index date. Adjusted odds ratios (ORs) and 95{\%} confidence intervals (CIs) were estimated by using multiple logistic regression. Results: Having been prescribed more than 28 defined daily dose (DDDs) of PPIs was associated with an increased risk for hip fracture in multivariate analyses (adjustments for matching variables and medication use) (at 29-70 DDDs, OR = 1.67, 95{\%} CI = 1.11-2.51 and at >70 DDDs, OR = 2.51, 95{\%} CI = 1.77-3.55). There was a significant trend toward increasing hip fracture risk with increasing cumulative DDDs of PPIs (p for trend <0.0001). Conclusions: This study provides evidence that PPIs use is associated with an increased risk of hip fracture in a dose-response manner.",
author = "Chiu, {Hui Fen} and Huang, {Ya Wen} and Chih-Ching Chang and Yang, {Chun Yuh}",
year = "2010",
month = "11",
day = "1",
doi = "10.1002/pds.2026",
language = "English",
volume = "19",
pages = "1131--1136",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

Use of proton pump inhibitors increased the risk of hip fracture : A population-based case-control study. / Chiu, Hui Fen; Huang, Ya Wen; Chang, Chih-Ching; Yang, Chun Yuh.

In: Pharmacoepidemiology and Drug Safety, Vol. 19, No. 11, 01.11.2010, p. 1131-1136.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Use of proton pump inhibitors increased the risk of hip fracture

T2 - A population-based case-control study

AU - Chiu, Hui Fen

AU - Huang, Ya Wen

AU - Chang, Chih-Ching

AU - Yang, Chun Yuh

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Purpose: To investigate whether the use of proton pump inhibitor (PPIs) was associated with an increased risk of hip fracture. Methods: We conducted a population-based case-control study in Taiwan. Data were retrospectively collected from the Taiwan National health Insurance Research Database. Cases included all patients with a newly diagnosed of hip fracture in 2005 and 2006 (n = 1241). The controls were pair matched to cases by age, sex, and index date. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by using multiple logistic regression. Results: Having been prescribed more than 28 defined daily dose (DDDs) of PPIs was associated with an increased risk for hip fracture in multivariate analyses (adjustments for matching variables and medication use) (at 29-70 DDDs, OR = 1.67, 95% CI = 1.11-2.51 and at >70 DDDs, OR = 2.51, 95% CI = 1.77-3.55). There was a significant trend toward increasing hip fracture risk with increasing cumulative DDDs of PPIs (p for trend <0.0001). Conclusions: This study provides evidence that PPIs use is associated with an increased risk of hip fracture in a dose-response manner.

AB - Purpose: To investigate whether the use of proton pump inhibitor (PPIs) was associated with an increased risk of hip fracture. Methods: We conducted a population-based case-control study in Taiwan. Data were retrospectively collected from the Taiwan National health Insurance Research Database. Cases included all patients with a newly diagnosed of hip fracture in 2005 and 2006 (n = 1241). The controls were pair matched to cases by age, sex, and index date. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by using multiple logistic regression. Results: Having been prescribed more than 28 defined daily dose (DDDs) of PPIs was associated with an increased risk for hip fracture in multivariate analyses (adjustments for matching variables and medication use) (at 29-70 DDDs, OR = 1.67, 95% CI = 1.11-2.51 and at >70 DDDs, OR = 2.51, 95% CI = 1.77-3.55). There was a significant trend toward increasing hip fracture risk with increasing cumulative DDDs of PPIs (p for trend <0.0001). Conclusions: This study provides evidence that PPIs use is associated with an increased risk of hip fracture in a dose-response manner.

UR - http://www.scopus.com/inward/record.url?scp=78049300965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049300965&partnerID=8YFLogxK

U2 - 10.1002/pds.2026

DO - 10.1002/pds.2026

M3 - Article

VL - 19

SP - 1131

EP - 1136

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 11

ER -